PG电子试玩平台

Media

Press Release

03
2022.08
Approval Of The Comparative Study Between ReCOV And mRNA Vaccines By FDA In The Philippines
27
2022.06
Clinical Trial Approval For mRNA Covid-19 Vaccine For Omicron Variant In The Philippines
02
2022.05
Clinical Trial Approval For ReCOV In The PRC And The Overseas Clinical Trial Progress Of ReCOV
13
2022.04
Receipt Of Approval From The UAE For Phase II/III Clinical Trial Of Sequential Booster Vaccination For ReCOV

Publications

2023.03.06
Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2
2022.05.11
The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV
2022.02.12
Lyophilized mRNA-lipid nanoparticles vaccine with long-term stability and high antigenicity against SARS-CoV-2
2021.11.09
A trimeric NTD and RBD SARS-CoV-2 subunit vaccine induced protective immunity in CAG-hACE2 transgenic mice and rhesus macaques
凯发体育官方网站手机 必威体育app官方官方最新 足球比分球盘皇冠唯一官方 贝博体育官方网址 瑞丰体育正规 ob欧博体育最新版 九州体育博彩官方登录 足球滚球盘正版 体育真人官方登录 >网站地图-sitemap